Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
676
mi
from
Birmingham, AL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
601
mi
from
Florence, AL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
601
mi
from
Florence, AL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
737
mi
from
Mobile, AL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
737
mi
from
Mobile, AL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
2732
mi
from
Anchorage, AK
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
2732
mi
from
Anchorage, AK
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
850
mi
from
Phoenix, AZ
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
850
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
833
mi
from
Tucson, AZ
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
833
mi
from
Tucson, AZ
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1205
mi
from
Fresno, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1205
mi
from
Fresno, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1114
mi
from
Loma Linda, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1114
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1172
mi
from
Long Beach, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1172
mi
from
Long Beach, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1161
mi
from
Newport Beach, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1161
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1123
mi
from
Riverside, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1123
mi
from
Riverside, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1139
mi
from
San Diego, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1139
mi
from
San Diego, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1177
mi
from
Sepulveda, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1177
mi
from
Sepulveda, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1176
mi
from
Torrance, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1176
mi
from
Torrance, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1357
mi
from
Hartford, CT
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1357
mi
from
Hartford, CT
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1109
mi
from
Bay Pines, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1109
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1126
mi
from
Brandon, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1126
mi
from
Brandon, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1105
mi
from
Clearwater, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1105
mi
from
Clearwater, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1171
mi
from
Cocoa, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1171
mi
from
Cocoa, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1306
mi
from
Fort Lauderdale, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1306
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1049
mi
from
Gainesville, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1149
mi
from
Kissimmee, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1149
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1144
mi
from
Orlando, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1144
mi
from
Orlando, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1140
mi
from
Winter Park, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1140
mi
from
Winter Park, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
816
mi
from
Lawrenceville, GA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
816
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
429
mi
from
Belleville, IL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
429
mi
from
Belleville, IL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
264
mi
from
Council Bluffs, IA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
264
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
32
mi
from
Wichita, KA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
32
mi
from
Wichita, KA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1148
mi
from
Baltimore, MD
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1134
mi
from
Columbia, MD
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1134
mi
from
Columbia, MD
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
827
mi
from
Livonia, MI
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
827
mi
from
Livonia, MI
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
559
mi
from
Fridley, MN
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
559
mi
from
Fridley, MN
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
551
mi
from
Minneapolis, MN
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
551
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
199
mi
from
Kansas City, MO
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
199
mi
from
Kansas City, MO
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
415
mi
from
Saint Louis, MO
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
220
mi
from
Lincoln, NE
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
220
mi
from
Lincoln, NE
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
262
mi
from
Omaha, NE
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
262
mi
from
Omaha, NE
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1057
mi
from
Buffalo, NY
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1057
mi
from
Buffalo, NY
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1195
mi
from
North Syracuse, NY
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1195
mi
from
North Syracuse, NY
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
957
mi
from
Charlotte, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
957
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1047
mi
from
Durham, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1047
mi
from
Durham, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1191
mi
from
Elizabeth City, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1191
mi
from
Elizabeth City, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
945
mi
from
Statesville, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
945
mi
from
Statesville, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
1141
mi
from
Wilmington, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
1141
mi
from
Wilmington, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
971
mi
from
Winston-Salem, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
971
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
899
mi
from
Canton, OH
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
899
mi
from
Canton, OH
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
727
mi
from
Cincinnati, OH
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
727
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
749
mi
from
Dayton, OH
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
749
mi
from
Dayton, OH
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
155
mi
from
Oklahoma City, OK
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
155
mi
from
Oklahoma City, OK
Click here to add this to my saved trials